Johnson & Johnson (JNJ)

These stocks are ready to pop higher.

Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest.

A steady dose of quality companies will keep your portfolio growing big and strong.

The search for consistent, predictable income is a constant for investors in both bull and bear markets. While traditional dividend stocks and bonds are reliable tools, a lesser-known but increasingly popular approach—known as the Option Wheel Strategy—is rapidly gaining traction among retail traders and seasoned professionals alike. This

Acadia Pharmaceuticals is working on its next-generation Nuplazid and, for CEO Catherine Owen Adams, the journey is personal.

Johnson & Johnson's 2025 outlook sees slight EPS and revenue upgrades, while headwinds from biosimilars and tariffs are expected to weigh on performance.

Johnson & Johnson (NYSE:JNJ) offers a reliable 3.33% dividend yield with strong profitability and financial health, making it a solid pick for dividend investors.

Pharmaceutical investors are being cautious, with concerns over potential supply disruptions, cost pressures, and uncertainty regarding policy implementation.

J&J gained access to Caplyta by the acquisition of Intra-Cellular Therapies, Inc., which was completed in April.

FDA issued an Early Alert for Abiomed's Automated Impella Controllers due to potential safety concerns following reports of 3 deaths.

Trump's $3.3 trillion domestic agenda bill, passed by the House on Thursday, includes a significant victory for pharmaceutical companies .

The Dow Jones Industrial Average stocks average a 2% dividend yield through the first six months of 2025. Here are the top yields.

A federal court denied Johnson & Johnson's motion to implement a 340B drug rebate model, siding with HHS and hospitals who argued it violated program intent.

The updated label applies to extended-release stimulants prescribed off-label to children under six, following data showing higher drug exposure and side effect rates in that age group.

FDA lifts REMS for approved CAR-T therapies, easing hospital restrictions and signaling broader future access in oncology and autoimmune treatment.

Forever is a tricky word in the stock market, but these stocks are as safe as they come and will pay you to hold them.